TABLE 2.
Detailed information on antiresorptive-related osteonecrosis of jaw reports.
| Zoledronic acid N (%) | Alendronate, N (%) | Denosumab, N (%) | Risedronate, N (%) | Ibandronate, N (%) | Pamidronate, N (%) | Romosozumab, N (%) | Etidronate, N (%) | ||
|---|---|---|---|---|---|---|---|---|---|
| Gender | F | 4149 (54.49) | 2025 (80.42) | 4095 (57.07) | 189 (86.30) | 420 (87.32) | 258 (65.98) | 16 (88.89) | 2 (66.67) |
| M | 2975 (39.07) | 249 (9.89) | 2079 (28.98) | 19 (8.68) | 30 (6.24) | 99 (25.32) | 1 (5.56) | 1 (33.33) | |
| Unknown | 490 (6.44) | 244 (9.69) | 1001 (13.95) | 11 (5.02) | 31 (6.44) | 34 (8.70) | 1 (5.56) | ||
| Age | N | 5994 | 1855 | 4648 | 155 | 357 | 150 | 901 | 2 |
| Median (Q1, Q3) | 66 (58, 74) | 69 (60, 77) | 71 (64, 78) | 73 (66, 81) | 73 (63, 80) | 65 (59, 75) | 65 (55,75) | 60 (60, 60) | |
| Continent | North America | 1468 (19.28) | 1508 (59.89) | 2193 (30.56) | 43 (17.55) | 0 | 14 (3.58) | 0 | 0 |
| Oceania | 59 (0.77) | 3 (0.12) | 214 (2.98) | 2 (0.82) | 4 (0.83) | 8 (2.05) | 0 | 0 | |
| Africa | 22 (0.29) | 0 | 2 (0.03) | 1 (0.41) | 250 (51.98) | 100 (25.58) | 1 (5.56) | ||
| South America | 178 (2.34) | 6 (0.24) | 61 (0.85) | 86 (35.10) | 62 (12.89) | 26 (6.65) | 12 (66.67) | 1 (33.33) | |
| Europe | 3901 (51.23) | 832 (33.04) | 3186 (44.40) | 64 (26.12) | 2 (0.42) | 2 (0.51) | 0 | 0 | |
| Asia | 1764 (23.17) | 158 (6.27) | 1516 (21.13) | 7 (2.86) | 0 | 0 | 0 | 0 | |
| Unknown | 222 (2.92) | 11 (0.44) | 3 (0.04) | 42 (17.14) | 163 (33.89) | 241 (61.64) | 5 (27.78) | 2 (66.67) | |
| Reporter | Physician | 1477 (19.40) | 814 (32.33) | 4254 (59.29) | 17 (7.20) | 191 (39.71) | 35 (8.95) | 15 (83.33) | 2 (66.67) |
| Other health-professional | 4473 (58.74) | 954 (37.89) | 1490 (20.77) | 90 (38.09) | 95 (19.75) | 135 (34.53) | 0 | 1 (33.33) | |
| Consumer | 939 (12.33) | 422 (16.76) | 1025 (14.29) | 30 (12.71) | 52 (10.81) | 0 | 1 (5.56) | 0 | |
| Pharmacist | 134 (1.76) | 36 (1.43) | 209 (2.91) | 26 (11.02) | 10 (2.08) | 4 (1.02) | 0 | 0 | |
| Lawyer | 63 (0.83) | 108 (4.29) | 6 (0.08) | 9 (3.81) | 61 (12.68) | 203 (51.92) | 0 | 0 | |
| Unknown | 528 (6.93) | 184 (7.31) | 191 (2.66) | 64 (27.12) | 72 (14.97) | 14 (3.58) | 2 (11.11) | 0 | |
| Indications | Tumor and Tumor-related | 4963 (90.02) | 35 (1.83) | 2877 (62.87) | 7 (4.64) | 92 (25.48) | 105 (88.24) | 0 (0.00) | 0 (0.00) |
| Osteoporosis-related | 550 (9.98) | 1877 (98.17) | 1699 (37.13) | 144 (95.36) | 269 (74.52) | 14 (11.76) | 16 (100.00) | 1 (100.00) | |
| Outcomes | Death | 604 (6.58) | 87 (2.05) | 213 (2.54) | 5 (1.69) | 8 (1.48) | 14 (2.30) | 0 (0.00) | 0 (0.00) |
| Disability | 665 (7.25) | 824 (19.44) | 355 (4.24) | 20 (6.76) | 40 (7.38) | 205 (33.61) | 1 (4.55) | 1 (4.55) | |
| Hospitalization - Initial or Prolonged | 1581 (17.23) | 1123 (26.49) | 989 (11.80) | 84 (28.38) | 110 (20.30) | 26 (4.26) | 4 (18.18) | 4 (18.18) | |
| Life-Threatening | 53 (0.58) | 24 (0.57) | 34 (0.41) | 9 (3.04) | 7 (1.29) | 2 (0.33) | 0 (0.00) | 0 (0.00) | |
| Other Serious (Important Medical Event) | 6272 (68.36) | 2181 (51.45) | 6789 (81.01) | 178 (60.14) | 377 (69.56) | 363 (59.51) | 17 (77.27) | 17 (77.27) |
N, number of reports containing the suspect drug and the suspect adverse drug reaction. Associations of different antiresorptive agents with osteonecrosis of the jaw.